BRIEF: Breton launches $30 million Hong Kong IPO
Construction machinery maker Breton Technology Co. Ltd. (1333.HK) launched its Hong Kong public offering Friday, announcing plans to sell 13 million shares for HK$18 apiece to raise HK$234 million ($30…
Delisting speculation, and a new tea listing
Speculation is growing on a potential delisting of Chinese shares from New York in the growing US-China trade war. Could such a mass delisting really happen? And a purist premium tea maker named Chagee raises $400 million in a Nasdaq IPO. What sets this company apart from its many rivals?
Undervalued CICC banks on Hong Kong IPO pickup
China’s largest underwriter of Hong Kong listings helped its clients to raise $3.84 billion last year, as it reportedly gets set to sponsor another blockbuster IPO by battery giant CATL…
BRIEF: PCB equipment maker Han’s CNC plans Hong Kong listing
Shenzhen-listed PCB equipment maker Shenzhen Han’s CNC Technology Co. Ltd. (301200.SZ) announced on Monday it plans to seek a listing on the Hong Kong Stock Exchange to enhance its competitiveness…
NEWS WRAP: Chagee raises $411 million in Nasdaq IPO
The listing was the first in the U.S. by a Chinese premium tea drink maker, which prides itself on the simplicity of its products and focus on the country’s ancient…
Ruanyun soars as China edtechs learn to live in new environment
The company’s AI-based homework and testing apps and 15.1 million users have helped it to stand out from rivals, though the stock looks expensive after a strong post-IPO rally Key…
BRIEF: Duality Biotherapies surges in Hong Kong trading debut
Shares of biotech firm Duality Biotherapeutics Inc. (9606.HK) opened up 91% at HK$181 on Tuesday and continued to climb in their Hong Kong trading debut, closing up 127% at HK$214.80…
Recent Articles
RELATED ARTICLES
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK -
BRIEF: WuXi XDC’s revenue, profit jump in 2024
2268.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
